This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

LeadingBiotech: Cancer Advance
March 5, 2020
Koch Institute for Integrative Cancer Research at MITCambridge, MA

Walter Olesiak
Partner at Remiges Ventures


Walter has over 28 years of experience in venture investments, business development and healthcare consulting. Walter is a founding Partner and Chief Operating Officer of Remiges Ventures, a cross-border venture firm focused on early stage therapeutic opportunities where he has served as interim President and board director for Omeicos Ophthalmics and board observer for ENB Therapeutics, both Remiges portfolio companies. Prior to Remiges, Walter spent 8 years with Mitsui Ventures, with board positions in 10 portfolio companies including Boston Biomedical (acquired by Dainippon Sumitomo), Actimis Pharmaceuticals (acquired by Boehringer Ingelheim), ProteinSimple (acquired by Bio-Techne). Prior to Mitsui Walter spent 6 years with Cambridge Pharma Consultancy advising on global pricing, reimbursement and market access issues to leading pharmaceutical and biotechnology companies. Prior to Cambridge, Walter spent 8 years in Tokyo in various roles with Genzyme Japan and SRL, Inc. Walter holds an AB in Biochemical Sciences from Harvard University and an MBA from Cornell University.

Agenda Sessions

  • A Review of the Cancer Research Ecosystem: Opportunities and Challenges